The microencapsulation can help deliver the benefits of lactoferrin by protecting it from degradation in conditions found in the stomach.
Bega Bionutrients said the Inferrin product opens up new benefits and applications for lactoferrin-based products including foods and dietary supplements.
Survives degradation in stomach
An initial pilot clinical trial on Inferrin has shown promising results, the company said. In a double-blind, randomized, controlled, cross-over trial in healthy males, Inferrin demonstrated effects on immune markers and the gut microbiome. The study also showed higher levels of lactoferrin in the faecal matter in those consuming Inferrin.
This suggests Inferrin is surviving degradation in the stomach and influencing the gut microbiome.
Variety of applications
Dr Bradley Coleman, business manager of Bega Bionutrients, said the company is already planning to commence a larger scale clinical study later this year to follow up on the results.
“Lactoferrin has been extensively studied and documented for its multiple health benefits in adults and infants. But as a protein, lactoferrin is at risk of being broken down in the mature stomach before it can reach the small intestine, where it is believed much of its activity takes place,” Dr Coleman said.
“Understanding this issue, we worked with Australian encapsulation company Progel Pty Ltd and the University of Queensland to develop a form of lactoferrin that is protected through the stomach and released intact in the small intestine.
“Using Progel’s novel and patented microencapsulation technology, we developed Inferrin - lactoferrin microencapsulated in common food grade materials. Inferrin will open new market opportunities for our customers and supports innovative product applications.”
Inferrin can be used in foods and dietary supplements. The microencapsulation technology allows Inferrin to be used in a wide variety of delivery formats including gels, powders and liquids, as well as the more traditional tablets and capsules.